What targeted therapies are available for Multiple Myeloma

Targeted Therapies for Multiple Myeloma

Targeted therapies are a cornerstone of multiple myeloma treatment. These drugs work by identifying and attacking specific features of myeloma cells, making them different from traditional chemotherapy. Let me walk you through the main categories and how they work.

How Targeted Therapy Works

According to the NCCN Guidelines for Patients, targeted therapy drugs work by finding specific vulnerabilities in myeloma cells. Here's a practical example: myeloma cells rely on structures called proteasomes to clear out waste proteins. If a proteasome inhibitor blocks this process, waste proteins build up inside the cell until it becomes overloaded and dies.

Main Categories of Targeted Therapies

1. Proteasome Inhibitors

These drugs block proteasomes—the "cleanup crew" that myeloma cells need to survive.

Examples include:

• Bortezomib (Velcade)
• Carfilzomib (Kyprolis)
• Ixazomib (Ninlaro)

These are often used in combination therapy and are considered preferred first-line treatments according to NCCN Guidelines.

2. Monoclonal Antibodies

These are artificial antibodies that attach to specific proteins on myeloma cells and recruit your immune system to attack them.

Examples include:

• Daratumumab (Darzalex) - one of the most commonly used
• Isatuximab-irfc (Sarclisa)
• Elotuzumab (Empliciti)

3. Immunomodulators

These drugs enhance your immune system's ability to fight myeloma cells.

Examples include:

• Lenalidomide (Revlimid)
• Pomalidomide (Pomalyst)
• Thalidomide (Thalomid)

4. Bispecific Antibodies (Newer Option)

These are dual-targeting drugs that attach to BOTH T cells (your immune cells) and myeloma cells, bringing them together so the T cells can attack the cancer.

Examples include:

• Teclistamab-cqyv (Tecvayli)
• Talquetamab-tgvs (Talvey)
• Elranatamab-bcmm (Elrexfio)

According to NCCN Guidelines, bispecific antibodies are preferred options for patients with relapsed or resistant myeloma who've tried at least 1-2 prior therapies.

5. CAR T-Cell Therapy

This is a personalized immunotherapy made from your own T cells. Scientists reprogram these cells to better recognize and attack myeloma cells.

Examples include:

• Idecabtagene vicleucel (Abecma)
• Ciltacabtagene autoleucel (Carvykti)

Per NCCN Guidelines, CAR T-cell therapy is a preferred option for certain patients with relapsed or resistant myeloma who've tried at least 1-2 other therapies.

6. Small Molecule Inhibitors

These are tiny drugs that can penetrate inside cancer cells to target specific proteins.

Example:

• Venetoclax (Venclexta)

7. Nuclear Export Inhibitors

These prevent proteins from leaving the nucleus of cancer cells, stopping the cells from functioning.

Example:

• Selinexor (Xpovio)

How These Are Used in Treatment

According to NCCN Guidelines, targeted therapies are typically given in combinations rather than alone. Common preferred combinations for initial treatment include:

• Daratumumab + bortezomib + lenalidomide + dexamethasone
• Daratumumab + lenalidomide + dexamethasone
• Carfilzomib + lenalidomide + dexamethasone

The specific combination your doctor recommends depends on factors like:

• Whether you're a candidate for a hematopoietic cell transplant
• Your overall health and fitness level
• Your kidney and heart function
• Previous treatments you've received

Side Effects to Know About

Common side effects of targeted therapies include:

• Fatigue and weakness
• Nausea, vomiting, diarrhea
• Headaches and chills
• Low blood cell counts (which increases infection risk)
• Peripheral neuropathy (numbness/tingling in hands or feet)
• Blood clots
• Skin rash

Important Questions to Ask Your Care Team

1. Which targeted therapy combination do you recommend for my specific situation, and why?
2. How will we know if the treatment is working, and how often will we check?
3. What side effects should I expect, and how will we manage them?
4. Are there any clinical trials of newer targeted therapies I should consider?
5. If this treatment stops working, what are my next options?

Key Takeaway

Multiple myeloma has many effective targeted therapy options available. The NCCN Guidelines emphasize that treatment should be individualized based on your specific disease characteristics, overall health, and goals. If one therapy doesn't work or stops working, there are typically other options to try—which is why having a myeloma specialist involved in your care is so valuable.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.